Table 2.
Total calories and macronutrient intake (median [range]) in LYM-X-SORB™ (LXS) and Placebo groups at baseline, 3 and 12 month.
| All n=52† |
LXS n=20 |
Placebo n=32 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 3 mo | 12 mo | Baseline | 3 mo | 12 mo | Baseline | 3 mo | 12 mo | |
| Total intake, kcal/d | 2502 [1478,4909] |
2581 [1609,3620] |
2616 [1660,4125] |
2561 [1841,3504] |
2678 [1731,3620] |
2611 [1660,4005] |
2437 [1478,4909] |
2440 [1609,3571] |
2623 [1704,4125] |
| EER, % | 123 [64,223] |
125 [77,221] |
122 [69,213] |
120 [86,153] |
125 [77,173] |
125 [69,165] |
127 [64,223] |
124 [77,221] |
120 [81,213] |
| Fat, g/d | 97 [54,227] |
97 [51,180] |
102 [59,203] |
109 [61,145] |
99 [66,173] |
93 [59,183] |
94 [54,227] |
96 [51,180] |
103 [69,203] |
| Fat, %kcal | 36 [23,53] |
34 [19,49] |
36 [27,47] |
36 [27,42] |
31 [24,49] |
35 [27,46] |
37 [23,53] |
35 [19,46] |
36 [28,47] |
| Protein, g/d | 82 [46,170] |
83 [38,137] |
86 [36,167] |
82 [54,119] |
85 [59,133] |
85 [36,135] |
80 [46,170] |
77 [38,137] |
86 [45,167] |
| Protein, %kcal | 13 [9,24] |
13 [8,19] |
13 [9,23] |
13 [9,20] |
13 [9,17] |
13 [9,17] |
13 [9,24] |
12 [8,19] |
13 [9,23] |
| Carbohydrates, g/d | 318 [179,604] |
349 [192,583] |
315 [203,559] |
325 [239,474] |
391 [192,522] |
325 [238,516] |
305 [179,604] |
347 [231,583] |
308 [203,559] |
| Carbohydrates, %kcal | 51 [34,69] |
53 [33,70] |
52 [38,63] |
52 [43,63] |
53 [33,66] |
52 [38,61] |
51 [34,69] |
53 [41,70] |
51 [39,63] |
†
Of the 63 subjects, 52 had complete dietary data; LXS and placebo supplement intake was adjusted for proximate adherence (diet intake not adjusted); EER – Estimated energy requirement